[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival].

PubMed 2026 Open access

Read full text
Authors: N N Liu, B Li, T J Qin, S Q Qu, L J Pan, M Jiao, Q Y Gao, J Y Zhao, Zhijian Xiao, Z F Xu
DOI: 10.3760/cma.j.cn121090-20250418-00188
Cited by: 0

Abstract

The present study confirms that the RR6 prognostic model has favorable prognostic predictive ability in Chinese patients with MF and can be utilized for the early identification of high-risk patients. The integration of HMR(mt) and RASp(mt) may enhance the predictive power of the RR6 model.

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
PubMed
Volume
47
Issue
1
Pages
50–56
Publication date
14 January 2026
Language
ZH